Welcome to our dedicated page for Humacyte SEC filings (Ticker: HUMAW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Humacyte, Inc. filings document the biotechnology company's acellular tissue platform, listed redeemable warrants and material corporate events. Form 8-K reports cover Nasdaq listing-compliance notices and amendments to distribution arrangements for the 6 millimeter acellular tissue engineered vessel-tyod, including worldwide development, commercialization and regulatory rights. Proxy materials cover board and shareholder voting matters, executive compensation, equity awards and governance. The filing record also identifies HUMAW as redeemable warrants, each whole warrant exercisable for one share of common stock at $11.50, traded on Nasdaq.
Fresenius Medical Care Holdings, Inc. and its parent Fresenius Medical Care AG report beneficial ownership of 18,312,735 shares of Humacyte common stock, equal to 6.8% of the outstanding voting shares. All 18,312,735 shares are issued, outstanding, and directly owned by Fresenius Medical Care Holdings, Inc., with Fresenius Medical Care AG as indirect sole shareholder and deemed beneficial owner.
The stake percentage decreased from 8.4% to 6.8% solely because Humacyte’s total outstanding common shares increased to 269,638,156 as of June 12, 2026; Fresenius has neither acquired nor disposed of Humacyte shares since its initial 2021 filing. The amendment also notes that Mollie Miller became a Vice President and Assistant Treasurer of Fresenius Medical Care Holdings, Inc. effective May 1, 2026.
Fresenius Medical Care Holdings, Inc. and its parent Fresenius Medical Care AG report beneficial ownership of 18,312,735 shares of Humacyte common stock, equal to 6.8% of the outstanding voting shares. All 18,312,735 shares are issued, outstanding, and directly owned by Fresenius Medical Care Holdings, Inc., with Fresenius Medical Care AG as indirect sole shareholder and deemed beneficial owner.
The stake percentage decreased from 8.4% to 6.8% solely because Humacyte’s total outstanding common shares increased to 269,638,156 as of June 12, 2026; Fresenius has neither acquired nor disposed of Humacyte shares since its initial 2021 filing. The amendment also notes that Mollie Miller became a Vice President and Assistant Treasurer of Fresenius Medical Care Holdings, Inc. effective May 1, 2026.
Humacyte, Inc. director Susan Richards Windham-Bannister received a grant of stock options covering 80,000 shares of common stock. The options carry an exercise price of 1.08 per share and expire on June 11, 2036.
According to the vesting terms, 25% of the option becomes exercisable on June 11, 2027. The remaining portion vests in equal monthly installments, with 1/48 of the option becoming exercisable on the 11th of each month through June 11, 2030. Following this grant, she holds 80,000 stock options directly.
Humacyte, Inc. director Susan Richards Windham-Bannister received a grant of stock options covering 80,000 shares of common stock. The options carry an exercise price of 1.08 per share and expire on June 11, 2036.
According to the vesting terms, 25% of the option becomes exercisable on June 11, 2027. The remaining portion vests in equal monthly installments, with 1/48 of the option becoming exercisable on the 11th of each month through June 11, 2030. Following this grant, she holds 80,000 stock options directly.
Humacyte, Inc. director Michael T. Constantino received a grant of stock options covering 80,000 shares of Common Stock. The options have an exercise price of $1.08 per share and expire on June 11, 2036. The first 25% vests on June 11, 2027, with the remaining portion vesting in equal monthly installments through June 11, 2030.
Humacyte, Inc. director Michael T. Constantino received a grant of stock options covering 80,000 shares of Common Stock. The options have an exercise price of $1.08 per share and expire on June 11, 2036. The first 25% vests on June 11, 2027, with the remaining portion vesting in equal monthly installments through June 11, 2030.
Humacyte, Inc. director Max N. Wallace received a grant of stock options for 80,000 shares of Common Stock. The options carry an exercise price of $1.08 per share and expire on June 11, 2036. Following this grant, he holds stock options covering 80,000 underlying shares.
The vesting is time-based: the first 25% of the option becomes exercisable on June 11, 2027, and the remaining portion vests in equal monthly installments (1/48 of the option) on the 11th of each month through June 11, 2030. This is a compensation-related award, not an open-market purchase or sale.
Humacyte, Inc. director Max N. Wallace received a grant of stock options for 80,000 shares of Common Stock. The options carry an exercise price of $1.08 per share and expire on June 11, 2036. Following this grant, he holds stock options covering 80,000 underlying shares.
The vesting is time-based: the first 25% of the option becomes exercisable on June 11, 2027, and the remaining portion vests in equal monthly installments (1/48 of the option) on the 11th of each month through June 11, 2030. This is a compensation-related award, not an open-market purchase or sale.
Humacyte, Inc. reported that President and CEO Laura E. Niklason had an indirect acquisition of stock options through her spouse. The grant covers 80,000 stock options for Humacyte common stock at an exercise price of $1.08 per share, expiring on June 11, 2036. According to the vesting schedule, the first 25% of the option becomes exercisable on June 11, 2027, and the remaining portion vests in equal monthly installments on the 11th of each month through June 11, 2030.
Humacyte, Inc. reported that President and CEO Laura E. Niklason had an indirect acquisition of stock options through her spouse. The grant covers 80,000 stock options for Humacyte common stock at an exercise price of $1.08 per share, expiring on June 11, 2036. According to the vesting schedule, the first 25% of the option becomes exercisable on June 11, 2027, and the remaining portion vests in equal monthly installments on the 11th of each month through June 11, 2030.
Humacyte, Inc. director Kathleen Sebelius reported a grant of stock options representing the right to buy 80,000 shares of common stock. The options have an exercise price of $1.08 per share and expire on June 11, 2036.
According to the vesting terms, the first 25% of the option becomes exercisable on June 11, 2027, and the remaining portion vests in equal monthly installments on the 11th of each month through June 11, 2030. Following this grant, Sebelius holds 80,000 stock options directly.
Humacyte, Inc. director Kathleen Sebelius reported a grant of stock options representing the right to buy 80,000 shares of common stock. The options have an exercise price of $1.08 per share and expire on June 11, 2036.
According to the vesting terms, the first 25% of the option becomes exercisable on June 11, 2027, and the remaining portion vests in equal monthly installments on the 11th of each month through June 11, 2030. Following this grant, Sebelius holds 80,000 stock options directly.
Humacyte, Inc. director Keith Anthony Jones received a grant of stock options for 80,000 shares of Common Stock. The options were awarded at an exercise price of $1.08 per share and are held directly. Following the grant, Jones holds 80,000 stock options.
According to the vesting terms, the first 25% of the option becomes exercisable on June 11, 2027. After that date, 1/48 of the option vests on the 11th of each month through June 11, 2030, with the option expiring on June 11, 2036. This is a compensation-related award rather than an open-market purchase or sale.
Humacyte, Inc. director Keith Anthony Jones received a grant of stock options for 80,000 shares of Common Stock. The options were awarded at an exercise price of $1.08 per share and are held directly. Following the grant, Jones holds 80,000 stock options.
According to the vesting terms, the first 25% of the option becomes exercisable on June 11, 2027. After that date, 1/48 of the option vests on the 11th of each month through June 11, 2030, with the option expiring on June 11, 2036. This is a compensation-related award rather than an open-market purchase or sale.
Humacyte, Inc. director Charles Bruce Green received a grant of stock options covering 80,000 shares of common stock. The options have an exercise price of $1.08 per share and expire on June 11, 2036. Following this grant, he holds 80,000 stock options directly.
According to the vesting terms, the first 25% of the option becomes exercisable on June 11, 2027, and the remaining portion vests in equal monthly installments through June 11, 2030. This is a compensation-related award rather than an open-market share purchase or sale.
Humacyte, Inc. director Charles Bruce Green received a grant of stock options covering 80,000 shares of common stock. The options have an exercise price of $1.08 per share and expire on June 11, 2036. Following this grant, he holds 80,000 stock options directly.
According to the vesting terms, the first 25% of the option becomes exercisable on June 11, 2027, and the remaining portion vests in equal monthly installments through June 11, 2030. This is a compensation-related award rather than an open-market share purchase or sale.
Humacyte director Diane Seimetz received a grant of stock options covering 80,000 shares of common stock. The options have an exercise price of $1.08 per share and expire on June 11, 2036. This is a compensation-related award, not an open-market purchase. Following the grant, she holds options on 80,000 shares directly. The footnote states that 25% of the options vest on June 11, 2027, with the remainder vesting in equal monthly installments through June 11, 2030.
Humacyte director Diane Seimetz received a grant of stock options covering 80,000 shares of common stock. The options have an exercise price of $1.08 per share and expire on June 11, 2036. This is a compensation-related award, not an open-market purchase. Following the grant, she holds options on 80,000 shares directly. The footnote states that 25% of the options vest on June 11, 2027, with the remainder vesting in equal monthly installments through June 11, 2030.
Humacyte, Inc. reported that director John Philip Bamforth received a grant of stock options covering 80,000 shares of common stock. The options have an exercise price of $1.08 per share and expire on June 11, 2036. Following this grant, he holds 80,000 options directly.
The footnote explains that 25% of the options become exercisable on June 11, 2027, with the remaining portion vesting in equal monthly installments (1/48 of the grant) on the 11th of each month through June 11, 2030. This is a compensation-related award rather than an open-market purchase.
Humacyte, Inc. reported that director John Philip Bamforth received a grant of stock options covering 80,000 shares of common stock. The options have an exercise price of $1.08 per share and expire on June 11, 2036. Following this grant, he holds 80,000 options directly.
The footnote explains that 25% of the options become exercisable on June 11, 2027, with the remaining portion vesting in equal monthly installments (1/48 of the grant) on the 11th of each month through June 11, 2030. This is a compensation-related award rather than an open-market purchase.